Helix BioPharma grants 1.3M stock options at $1.63 per share, cancels 2.2M options previously granted. The company advances oncology pipeline with L-DOS47 and GEMCEDA.
This news matters because stock option grants and cancellations signal management's confidence in the company's future and align executive interests with shareholder value. For investors, it indicates potential growth in Helix's pipeline, which includes promising therapies for hard-to-treat cancers like L-DOS47 and GEMCEDA. These developments could lead to breakthroughs in oncology, impacting patients and healthcare systems.
